http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 08 Jul 2026 09:08:37 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Ultragenyx+releases+2025+impact+report+on+rare+disease+programs/26745339.html <p>Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) published its 2025 Impact Report on July 8, 2026, covering the company's activities from January 1 through December 31, 2025, across areas including innovation, patients, workforce, communities, environmental practices, and governance.</p> <p>The Novato, California-based company reported that it advanced five investigational therapies in pivotal clinical programs during 2025, with trials conducted across more than 160 clinical trial sites in 19 countries. Ultragenyx invested approximately 62% of its operating expenses in research and development during the year.</p> <p>The company stated that more than 700 patients in 50 countries have been supported through expanded access and patient assistance programs http://www.streetinsider.com/FDA/Ultragenyx+releases+2025+impact+report+on+rare+disease+programs/26745339.html Wed, 08 Jul 2026 09:08:37 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/FDA/Ultragenyx+releases+2025+impact+report+on+rare+disease+programs/26745339.html <p>Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) published its 2025 Impact Report on July 8, 2026, covering the company's activities from January 1 through December 31, 2025, across areas including innovation, patients, workforce, communities, environmental practices, and governance.</p> <p>The Novato, California-based company reported that it advanced five investigational therapies in pivotal clinical programs during 2025, with trials conducted across more than 160 clinical trial sites in 19 countries. Ultragenyx invested approximately 62% of its operating expenses in research and development during the year.</p> <p>The company stated that more than 700 patients in 50 countries have been supported through expanded access and patient assistance programs http://www.streetinsider.com/FDA/Ultragenyx+releases+2025+impact+report+on+rare+disease+programs/26745339.html Wed, 08 Jul 2026 09:08:37 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/FDA/Ultragenyx+releases+2025+impact+report+on+rare+disease+programs/26745339.html <p>Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) published its 2025 Impact Report on July 8, 2026, covering the company's activities from January 1 through December 31, 2025, across areas including innovation, patients, workforce, communities, environmental practices, and governance.</p> <p>The Novato, California-based company reported that it advanced five investigational therapies in pivotal clinical programs during 2025, with trials conducted across more than 160 clinical trial sites in 19 countries. Ultragenyx invested approximately 62% of its operating expenses in research and development during the year.</p> <p>The company stated that more than 700 patients in 50 countries have been supported through expanded access and patient assistance programs http://www.streetinsider.com/FDA/Ultragenyx+releases+2025+impact+report+on+rare+disease+programs/26745339.html Wed, 08 Jul 2026 09:08:37 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/FDA/Ultragenyx+releases+2025+impact+report+on+rare+disease+programs/26745339.html <p>Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) published its 2025 Impact Report on July 8, 2026, covering the company's activities from January 1 through December 31, 2025, across areas including innovation, patients, workforce, communities, environmental practices, and governance.</p> <p>The Novato, California-based company reported that it advanced five investigational therapies in pivotal clinical programs during 2025, with trials conducted across more than 160 clinical trial sites in 19 countries. Ultragenyx invested approximately 62% of its operating expenses in research and development during the year.</p> <p>The company stated that more than 700 patients in 50 countries have been supported through expanded access and patient assistance programs http://www.streetinsider.com/FDA/Ultragenyx+releases+2025+impact+report+on+rare+disease+programs/26745339.html Wed, 08 Jul 2026 09:08:37 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/FDA/Ultragenyx+releases+2025+impact+report+on+rare+disease+programs/26745339.html <p>Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) published its 2025 Impact Report on July 8, 2026, covering the company's activities from January 1 through December 31, 2025, across areas including innovation, patients, workforce, communities, environmental practices, and governance.</p> <p>The Novato, California-based company reported that it advanced five investigational therapies in pivotal clinical programs during 2025, with trials conducted across more than 160 clinical trial sites in 19 countries. Ultragenyx invested approximately 62% of its operating expenses in research and development during the year.</p> <p>The company stated that more than 700 patients in 50 countries have been supported through expanded access and patient assistance programs http://www.streetinsider.com/FDA/Ultragenyx+releases+2025+impact+report+on+rare+disease+programs/26745339.html Wed, 08 Jul 2026 09:08:37 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/FDA/Ultragenyx+releases+2025+impact+report+on+rare+disease+programs/26745339.html <p>Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) published its 2025 Impact Report on July 8, 2026, covering the company's activities from January 1 through December 31, 2025, across areas including innovation, patients, workforce, communities, environmental practices, and governance.</p> <p>The Novato, California-based company reported that it advanced five investigational therapies in pivotal clinical programs during 2025, with trials conducted across more than 160 clinical trial sites in 19 countries. Ultragenyx invested approximately 62% of its operating expenses in research and development during the year.</p> <p>The company stated that more than 700 patients in 50 countries have been supported through expanded access and patient assistance programs http://www.streetinsider.com/FDA/Ultragenyx+releases+2025+impact+report+on+rare+disease+programs/26745339.html Wed, 08 Jul 2026 09:08:37 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/Press+Releases/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html <p>NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its <a target="_blank" href="https://www.globenewswire.com/Tracker?data=djHjenEnebWgQUWMQQKAfj2sCKYmv5aRTB-9eVtyHG0vfH7qPpkZ0DN088Dx_fm39Vx6wbRu3xfGNcBCv6FPB0Db4En0IiOf8-dyHvySmqTf2SpgoOR8E7PZPeaDqio6uJPx5MDR4g1gHy2LKjPNB9eugfzjVH59LZ1vqftiAmY=" rel="nofollow" target="_blank">2025 Impact Report</a>, detailing the company&apos;s work on behalf of patients and families living with rare and ultra-rare diseases. In 2025, Ultragenyx advanced five investigational therapies in pivotal clinical programs with the potential to reach tens of thousands of patients around the world — while continuing to build on years of work to support patients who cannot yet access approved treatments, which have now reached individuals in 50 countries.</p> <p>“The rare disease community has waited long enough — http://www.streetinsider.com/Press+Releases/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html Wed, 08 Jul 2026 09:08:00 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/Press+Releases/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html <p>NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its <a target="_blank" href="https://www.globenewswire.com/Tracker?data=djHjenEnebWgQUWMQQKAfj2sCKYmv5aRTB-9eVtyHG0vfH7qPpkZ0DN088Dx_fm39Vx6wbRu3xfGNcBCv6FPB0Db4En0IiOf8-dyHvySmqTf2SpgoOR8E7PZPeaDqio6uJPx5MDR4g1gHy2LKjPNB9eugfzjVH59LZ1vqftiAmY=" rel="nofollow" target="_blank">2025 Impact Report</a>, detailing the company&apos;s work on behalf of patients and families living with rare and ultra-rare diseases. In 2025, Ultragenyx advanced five investigational therapies in pivotal clinical programs with the potential to reach tens of thousands of patients around the world — while continuing to build on years of work to support patients who cannot yet access approved treatments, which have now reached individuals in 50 countries.</p> <p>“The rare disease community has waited long enough — http://www.streetinsider.com/Press+Releases/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html Wed, 08 Jul 2026 09:08:00 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/Press+Releases/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html <p>NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its <a target="_blank" href="https://www.globenewswire.com/Tracker?data=djHjenEnebWgQUWMQQKAfj2sCKYmv5aRTB-9eVtyHG0vfH7qPpkZ0DN088Dx_fm39Vx6wbRu3xfGNcBCv6FPB0Db4En0IiOf8-dyHvySmqTf2SpgoOR8E7PZPeaDqio6uJPx5MDR4g1gHy2LKjPNB9eugfzjVH59LZ1vqftiAmY=" rel="nofollow" target="_blank">2025 Impact Report</a>, detailing the company&apos;s work on behalf of patients and families living with rare and ultra-rare diseases. In 2025, Ultragenyx advanced five investigational therapies in pivotal clinical programs with the potential to reach tens of thousands of patients around the world — while continuing to build on years of work to support patients who cannot yet access approved treatments, which have now reached individuals in 50 countries.</p> <p>“The rare disease community has waited long enough — http://www.streetinsider.com/Press+Releases/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html Wed, 08 Jul 2026 09:08:00 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/Press+Releases/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html <p>NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its <a target="_blank" href="https://www.globenewswire.com/Tracker?data=djHjenEnebWgQUWMQQKAfj2sCKYmv5aRTB-9eVtyHG0vfH7qPpkZ0DN088Dx_fm39Vx6wbRu3xfGNcBCv6FPB0Db4En0IiOf8-dyHvySmqTf2SpgoOR8E7PZPeaDqio6uJPx5MDR4g1gHy2LKjPNB9eugfzjVH59LZ1vqftiAmY=" rel="nofollow" target="_blank">2025 Impact Report</a>, detailing the company&apos;s work on behalf of patients and families living with rare and ultra-rare diseases. In 2025, Ultragenyx advanced five investigational therapies in pivotal clinical programs with the potential to reach tens of thousands of patients around the world — while continuing to build on years of work to support patients who cannot yet access approved treatments, which have now reached individuals in 50 countries.</p> <p>“The rare disease community has waited long enough — http://www.streetinsider.com/Press+Releases/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html Wed, 08 Jul 2026 09:08:00 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/Press+Releases/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html <p>NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its <a target="_blank" href="https://www.globenewswire.com/Tracker?data=djHjenEnebWgQUWMQQKAfj2sCKYmv5aRTB-9eVtyHG0vfH7qPpkZ0DN088Dx_fm39Vx6wbRu3xfGNcBCv6FPB0Db4En0IiOf8-dyHvySmqTf2SpgoOR8E7PZPeaDqio6uJPx5MDR4g1gHy2LKjPNB9eugfzjVH59LZ1vqftiAmY=" rel="nofollow" target="_blank">2025 Impact Report</a>, detailing the company&apos;s work on behalf of patients and families living with rare and ultra-rare diseases. In 2025, Ultragenyx advanced five investigational therapies in pivotal clinical programs with the potential to reach tens of thousands of patients around the world — while continuing to build on years of work to support patients who cannot yet access approved treatments, which have now reached individuals in 50 countries.</p> <p>“The rare disease community has waited long enough — http://www.streetinsider.com/Press+Releases/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html Wed, 08 Jul 2026 09:08:00 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/Press+Releases/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html <p>NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its <a target="_blank" href="https://www.globenewswire.com/Tracker?data=djHjenEnebWgQUWMQQKAfj2sCKYmv5aRTB-9eVtyHG0vfH7qPpkZ0DN088Dx_fm39Vx6wbRu3xfGNcBCv6FPB0Db4En0IiOf8-dyHvySmqTf2SpgoOR8E7PZPeaDqio6uJPx5MDR4g1gHy2LKjPNB9eugfzjVH59LZ1vqftiAmY=" rel="nofollow" target="_blank">2025 Impact Report</a>, detailing the company&apos;s work on behalf of patients and families living with rare and ultra-rare diseases. In 2025, Ultragenyx advanced five investigational therapies in pivotal clinical programs with the potential to reach tens of thousands of patients around the world — while continuing to build on years of work to support patients who cannot yet access approved treatments, which have now reached individuals in 50 countries.</p> <p>“The rare disease community has waited long enough — http://www.streetinsider.com/Press+Releases/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html Wed, 08 Jul 2026 09:08:00 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/Globe+Newswire/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html <p>NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its <a target="_blank" href="https://www.globenewswire.com/Tracker?data=djHjenEnebWgQUWMQQKAfj2sCKYmv5aRTB-9eVtyHG0vfH7qPpkZ0DN088Dx_fm39Vx6wbRu3xfGNcBCv6FPB0Db4En0IiOf8-dyHvySmqTf2SpgoOR8E7PZPeaDqio6uJPx5MDR4g1gHy2LKjPNB9eugfzjVH59LZ1vqftiAmY=" rel="nofollow" target="_blank">2025 Impact Report</a>, detailing the company&apos;s work on behalf of patients and families living with rare and ultra-rare diseases. In 2025, Ultragenyx advanced five investigational therapies in pivotal clinical programs with the potential to reach tens of thousands of patients around the world — while continuing to build on years of work to support patients who cannot yet access approved treatments, which have now reached individuals in 50 countries.</p> <p>“The rare disease community has waited long enough — http://www.streetinsider.com/Globe+Newswire/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html Wed, 08 Jul 2026 09:08:00 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/Globe+Newswire/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html <p>NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its <a target="_blank" href="https://www.globenewswire.com/Tracker?data=djHjenEnebWgQUWMQQKAfj2sCKYmv5aRTB-9eVtyHG0vfH7qPpkZ0DN088Dx_fm39Vx6wbRu3xfGNcBCv6FPB0Db4En0IiOf8-dyHvySmqTf2SpgoOR8E7PZPeaDqio6uJPx5MDR4g1gHy2LKjPNB9eugfzjVH59LZ1vqftiAmY=" rel="nofollow" target="_blank">2025 Impact Report</a>, detailing the company&apos;s work on behalf of patients and families living with rare and ultra-rare diseases. In 2025, Ultragenyx advanced five investigational therapies in pivotal clinical programs with the potential to reach tens of thousands of patients around the world — while continuing to build on years of work to support patients who cannot yet access approved treatments, which have now reached individuals in 50 countries.</p> <p>“The rare disease community has waited long enough — http://www.streetinsider.com/Globe+Newswire/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html Wed, 08 Jul 2026 09:08:00 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/Globe+Newswire/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html <p>NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its <a target="_blank" href="https://www.globenewswire.com/Tracker?data=djHjenEnebWgQUWMQQKAfj2sCKYmv5aRTB-9eVtyHG0vfH7qPpkZ0DN088Dx_fm39Vx6wbRu3xfGNcBCv6FPB0Db4En0IiOf8-dyHvySmqTf2SpgoOR8E7PZPeaDqio6uJPx5MDR4g1gHy2LKjPNB9eugfzjVH59LZ1vqftiAmY=" rel="nofollow" target="_blank">2025 Impact Report</a>, detailing the company&apos;s work on behalf of patients and families living with rare and ultra-rare diseases. In 2025, Ultragenyx advanced five investigational therapies in pivotal clinical programs with the potential to reach tens of thousands of patients around the world — while continuing to build on years of work to support patients who cannot yet access approved treatments, which have now reached individuals in 50 countries.</p> <p>“The rare disease community has waited long enough — http://www.streetinsider.com/Globe+Newswire/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html Wed, 08 Jul 2026 09:08:00 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/Globe+Newswire/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html <p>NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its <a target="_blank" href="https://www.globenewswire.com/Tracker?data=djHjenEnebWgQUWMQQKAfj2sCKYmv5aRTB-9eVtyHG0vfH7qPpkZ0DN088Dx_fm39Vx6wbRu3xfGNcBCv6FPB0Db4En0IiOf8-dyHvySmqTf2SpgoOR8E7PZPeaDqio6uJPx5MDR4g1gHy2LKjPNB9eugfzjVH59LZ1vqftiAmY=" rel="nofollow" target="_blank">2025 Impact Report</a>, detailing the company&apos;s work on behalf of patients and families living with rare and ultra-rare diseases. In 2025, Ultragenyx advanced five investigational therapies in pivotal clinical programs with the potential to reach tens of thousands of patients around the world — while continuing to build on years of work to support patients who cannot yet access approved treatments, which have now reached individuals in 50 countries.</p> <p>“The rare disease community has waited long enough — http://www.streetinsider.com/Globe+Newswire/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html Wed, 08 Jul 2026 09:08:00 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/Globe+Newswire/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html <p>NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its <a target="_blank" href="https://www.globenewswire.com/Tracker?data=djHjenEnebWgQUWMQQKAfj2sCKYmv5aRTB-9eVtyHG0vfH7qPpkZ0DN088Dx_fm39Vx6wbRu3xfGNcBCv6FPB0Db4En0IiOf8-dyHvySmqTf2SpgoOR8E7PZPeaDqio6uJPx5MDR4g1gHy2LKjPNB9eugfzjVH59LZ1vqftiAmY=" rel="nofollow" target="_blank">2025 Impact Report</a>, detailing the company&apos;s work on behalf of patients and families living with rare and ultra-rare diseases. In 2025, Ultragenyx advanced five investigational therapies in pivotal clinical programs with the potential to reach tens of thousands of patients around the world — while continuing to build on years of work to support patients who cannot yet access approved treatments, which have now reached individuals in 50 countries.</p> <p>“The rare disease community has waited long enough — http://www.streetinsider.com/Globe+Newswire/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html Wed, 08 Jul 2026 09:08:00 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/Globe+Newswire/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html <p>NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its <a target="_blank" href="https://www.globenewswire.com/Tracker?data=djHjenEnebWgQUWMQQKAfj2sCKYmv5aRTB-9eVtyHG0vfH7qPpkZ0DN088Dx_fm39Vx6wbRu3xfGNcBCv6FPB0Db4En0IiOf8-dyHvySmqTf2SpgoOR8E7PZPeaDqio6uJPx5MDR4g1gHy2LKjPNB9eugfzjVH59LZ1vqftiAmY=" rel="nofollow" target="_blank">2025 Impact Report</a>, detailing the company&apos;s work on behalf of patients and families living with rare and ultra-rare diseases. In 2025, Ultragenyx advanced five investigational therapies in pivotal clinical programs with the potential to reach tens of thousands of patients around the world — while continuing to build on years of work to support patients who cannot yet access approved treatments, which have now reached individuals in 50 countries.</p> <p>“The rare disease community has waited long enough — http://www.streetinsider.com/Globe+Newswire/Ultragenyx+Releases+2025+Impact+Report+Emphasizing+Commitment+to+Rare+Disease+Patients%2C+Innovation%2C+and+Global+Impact/26745336.html Wed, 08 Jul 2026 09:08:00 -0400 A.60012006 A.60012011 O.08633450 O.31403954 O.37892119 RARE http://www.streetinsider.com/Analyst+PT+Change/Ultragenyx+Pharma+%28RARE%29+PT+Raised+to+%2440+at+RBC+Capital/26738652.html RBC Capital analyst Luca Issi raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $40.00 (from $35.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Ultragenyx+Pharma+%28RARE%29+PT+Raised+to+%2440+at+RBC+Capital/26738652.html Tue, 07 Jul 2026 07:59:39 -0400 RARE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ultragenyx+Pharmaceutica++For%3A+Jul+01++Filed+by%3A+Horn+Howard/26735182.html si-local-file:///var/storage/secattach/20260706/26735182.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ultragenyx+Pharmaceutica++For%3A+Jul+01++Filed+by%3A+Horn+Howard/26735182.html Mon, 06 Jul 2026 15:37:00 -0400 O.08633450 RARE http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ultragenyx+Pharmaceutica++For%3A+Jul+01++Filed+by%3A+Horn+Howard/26735182.html si-local-file:///var/storage/secattach/20260706/26735182.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ultragenyx+Pharmaceutica++For%3A+Jul+01++Filed+by%3A+Horn+Howard/26735182.html Mon, 06 Jul 2026 15:37:00 -0400 O.08633450 RARE http://www.streetinsider.com/SEC+Filings/Form++144++++++++Ultragenyx+Pharmaceutica+++++++++++++++Filed+by%3A+Horn+Howard/26720976.html si-local-file:///var/storage/secattach/20260701/26720976.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Ultragenyx+Pharmaceutica+++++++++++++++Filed+by%3A+Horn+Howard/26720976.html Wed, 01 Jul 2026 16:19:00 -0400 O.08633450 RARE http://www.streetinsider.com/SEC+Filings/Form++144++++++++Ultragenyx+Pharmaceutica+++++++++++++++Filed+by%3A+Horn+Howard/26720976.html si-local-file:///var/storage/secattach/20260701/26720976.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Ultragenyx+Pharmaceutica+++++++++++++++Filed+by%3A+Horn+Howard/26720976.html Wed, 01 Jul 2026 16:19:00 -0400 O.08633450 RARE http://www.streetinsider.com/Board+Changes/Calidi+Biotherapeutics+adds+biopharma+veteran+Corsee+Sanders+to+board/26676138.html <p>Calidi Biotherapeutics, Inc. (NYSE American: CLDI) announced the appointment of Corsee Sanders, Ph.D., to its Board of Directors, effective June 17, 2026, according to a company statement. She will serve as an independent director.</p> <p>Sanders brings more than three decades of biopharmaceutical experience. She spent 23 years at Genentech/Roche, where she held several leadership roles, including Senior Vice President and Global Head of Clinical Operations and Industry Collaboration for six years.</p> <p>Following Celgene's acquisition of Juno Therapeutics, Sanders served as strategic advisor to Celgene's Chief Medical Officer. She had previously been Executive Vice President of Development Operations at Juno. She also served http://www.streetinsider.com/Board+Changes/Calidi+Biotherapeutics+adds+biopharma+veteran+Corsee+Sanders+to+board/26676138.html Tue, 23 Jun 2026 08:00:36 -0400 LEGN RARE http://www.streetinsider.com/Board+Changes/Calidi+Biotherapeutics+adds+biopharma+veteran+Corsee+Sanders+to+board/26676138.html <p>Calidi Biotherapeutics, Inc. (NYSE American: CLDI) announced the appointment of Corsee Sanders, Ph.D., to its Board of Directors, effective June 17, 2026, according to a company statement. She will serve as an independent director.</p> <p>Sanders brings more than three decades of biopharmaceutical experience. She spent 23 years at Genentech/Roche, where she held several leadership roles, including Senior Vice President and Global Head of Clinical Operations and Industry Collaboration for six years.</p> <p>Following Celgene's acquisition of Juno Therapeutics, Sanders served as strategic advisor to Celgene's Chief Medical Officer. She had previously been Executive Vice President of Development Operations at Juno. She also served http://www.streetinsider.com/Board+Changes/Calidi+Biotherapeutics+adds+biopharma+veteran+Corsee+Sanders+to+board/26676138.html Tue, 23 Jun 2026 08:00:36 -0400 LEGN RARE